GlassScriptPhysician profile
Angela Marie Parrish
NPI 1700612389
$1,493.40
in general payments reported to CMS, 2019-2025
24 companies · $1,213 in 2025
The $1,213 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $281 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,493.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $228.40 | 2024-2025 | |
| Novocure INC. | $152.06 | 2024-2025 | Optune Lua (Novottf-200t), Optune |
| Jazz Pharmaceuticals INC. | $133.20 | 2025 | |
| Beigene USA, INC. | $125.00 | 2024 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $118.95 | 2025 | Tagrisso, Calquence |
| Incyte Corporation | $118.81 | 2024-2025 | Monjuvi, Zynyz, Jakafi |
| Astellas Pharma US INC | $103.40 | 2025 | Vyloy |
| Daiichi Sankyo INC. | $87.02 | 2025 | Datroway, Enhertu |
| Aveo Pharmaceuticals, INC. | $79.58 | 2025 | |
| Eisai INC. | $44.44 | 2025 | |
| Janssen Biotech, INC. | $28.70 | 2025 | Rybrevant |
| Regeneron Healthcare Solutions, INC. | $26.59 | 2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $25.45 | 2024 | Iclusig |
| Alexion Pharmaceuticals, INC. | $23.54 | 2025 | Ultomiris |
| Taiho Oncology, INC. | $22.84 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $22.30 | 2025 | Orserdu |
| Kyowa Kirin, INC. | $21.62 | 2025 | |
| Servier Pharmaceuticals LLC | $20.68 | 2025 | |
| Genmab U.S., INC. | $20.17 | 2025 | Epkinly |
| Agios Pharmaceuticals, INC. | $20.09 | 2025 | Pyrukynd |
| Genentech USA, INC. | $19.98 | 2024 | Venclexta |
| Emd Serono, INC. | $17.90 | 2025 | |
| Genzyme Corporation | $16.87 | 2024 | |
| Immunocore Limited | $15.81 | 2025 | Kimmtrak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Parrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.